Development of a bispecific antibody targeting PD-L1 and TIGIT …
网页2022年10月26日 · It is rational to construct bispecific antibodies targeting PD-L1 and TIGIT, besides retaining the efficacy of the combination therapy, bispecific antibodies (BsAbs) can provide a new...
Discovery of a novel anti PD-L1 X TIGIT bispecific antibody for …
网页We generated a novel single chain Fab heterodimeric bispecific IgG antibody format targeting PD-L1 and TIGIT with one binding site for each target antigen. The bispecifc antibody BiAb-1 is based on "knob-into-hole" technology for heavy chain heterodimerization with a glycine serine linker connecting the 3' end of Cκand the 5' end of VH to ...
Development of a bispecific antibody targeting PD-L1 and TIGIT …
网页2022年10月26日 · Programmed death-ligand 1 (PD-L1) and T cell immunoreceptor with Ig and ITIM domains (TIGIT) are two potential targets for cancer immunotherapy, early clinical studies showed the combination therapy of anti-PD-L1 and anti-TIGIT had synergistic efficacy both in the terms of overall response rate (ORR ….
PD-L1/TIGIT bispecific antibody showed survival advantage in …
网页PD-L1/TIGIT bispecific antibody showed survival advantage in animal model. Clin Transl Med. 2022 May;12 (5):e754. doi: 10.1002/ctm2.754. Authors. Songlin Mu 1 2 , Zhijuan Liang 1 2 , Yongmei Wang 1 2 , Wendi Chu 1 2 , Yi-Li Chen 3 4 , Qi Wang 1 2 , Guifeng Wang 1 2 , Chunhe Wang 1 2 3. Affiliations.
网页It is rational to construct bispecific antibodies targeting PD‐L1 and TIGIT, besides retaining the eficacy of the combination therapy, bispecific antibodies (BsAbs) can provide a new...
Co-engagement of TIGIT+ immune cells to PD-L1+ tumours by a bispecific …
网页2023年5月14日 · Here we demonstrate that a bispecific antibody (BsAb) targeting PD-L1 and TIGIT, HB0036, shows major advantages over the combination of the two parental monoclonal Abs (mAbs). We demonstrated that HB0036 co-engages PD-L1+ tumour cells and TIGIT+ T cells, and thereby upregulates CD226 …
Discovery of a novel anti PD-L1 X TIGIT bispecific antibody for the ...
网页2021年1月1日 · A novel ScFab bispecific antibody BiAb-1 targeting PD-L1 x TIGIT was generated in the present work. •. BiAb-1 shows active biochemical binding and blocking ability in vitro. •. BiAb-1 prescription shows significantly antitumor effect in multiple solid tumor models in vivo. Abstract.
PD‐L1/TIGIT bispecific antibody showed survival advantage in …
网页2022年5月6日 · We reported here a novel bispecific anti-PD-L1/TIGIT antibody with potent effects in enhancing human IL-2 production by primary human T cells in vitro and in increasing the overall survival in a transgenic mouse model in vivo.
Phase I/II safety and preliminary efficacy of PM1022, a bispecific ...
网页2024年5月29日 · Background: PM1022 is an anti-PD-L1 × TIGIT bispecific antibody that is engineered with a fully human IgG targeting TIGIT in an IgG1 wild type Fc backbone, fused to a VHH at the c-terminus targeting PD-L1. The potential MOA includes releasing T cell inhibition by blocking both the PD-L1/PD-1 and CD155/CD112/TIGIT pathways, as well …
Development of a bispecific antibody targeting PD-L1 and TIGIT …
网页2022年10月26日 · Here, we developed a tetravalent bispecific antibody targeting PD-L1 and TIGIT, armed with a fully functional Fc. We took the advantage of VHH to select the best bispecific antibody format and linker with optimal developability and cytotoxicity.